Identify the true and false statements about the use of lithium to treat bipolar disorders.

1. Schioldann J. History of the Introduction of Lithium into Medicine and Psychiatry. Adelaide Academic Press; Adelaide, Australia: 2009. [Google Scholar]

2. Cade JFJ. Lithium salts in the treatment of psychotic excitement. The Medical Journal of Australia. 1949;2:349–351. [PubMed] [Google Scholar]

3. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002;159:1005–1010. [PubMed] [Google Scholar]

4. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord. 2009;118:224–228. [PubMed] [Google Scholar]

5. Wyatt RJ, Henter ID, Jamison JC. Lithium revisited: savings brought about by the use of lithium, 1970–1991. Psychiatric Q. 2001;72:149–166. [PMC free article] [PubMed] [Google Scholar]

6. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217–222. [PubMed] [Google Scholar]

7. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. in press. [PMC free article] [PubMed] [Google Scholar]

8. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. [PubMed] [Google Scholar]

9. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–940. [PubMed] [Google Scholar]

10. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409–1413. [PubMed] [Google Scholar]

11. Muller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology. 2010;62:43–49. [PubMed] [Google Scholar]

12. Ahrens B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiat. 2001;34:132–136. [PubMed] [Google Scholar]

13. Grof P, Grof E. Varieties of lithium benefit. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:689–696. [PubMed] [Google Scholar]

14. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1–44. [PubMed] [Google Scholar]

15. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537. [PubMed] [Google Scholar]

16. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012;14(Suppl 2):37–50. [PubMed] [Google Scholar]

17. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130:452–469. [PubMed] [Google Scholar]

18. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–728. [PubMed] [Google Scholar]

19. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135–153. [PubMed] [Google Scholar]

20. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther. 2010;128:281–304. [PMC free article] [PubMed] [Google Scholar]

21. Gray JD, McEwen BS. Lithium’s role in neural plasticity and its implications for mood disorders. Acta Psychiatr Scand. 2013;128:347–361. [PMC free article] [PubMed] [Google Scholar]

22. Lenox RH, Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry. 2003;8:135–144. [PubMed] [Google Scholar]

23. Shorter E. The 25th anniversary of the launch of Prozac gives pause for thought: where did we go wrong? Br J Psychiatry. 2014;204:331–332. [PubMed] [Google Scholar]

24. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry. 2000;57:187–190. [PubMed] [Google Scholar]

25. Grof P, Alda M. Discrepancies in the efficacy of lithium. Arch Gen Psychiatry. 2000;57:191. [PubMed] [Google Scholar]

26. Kleindienst N, Greil W. Lithium in the long-term treatment of bipolar disorders. Eur Arch Psychiatr Clin Neurosci. 2003;253:120–125. [PubMed] [Google Scholar]

27. Rybakowski JK, Chlopocka-Wozniak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord. 2001;3:63–70. [PubMed] [Google Scholar]

28. Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS ONE. 2013;8:e65636. [PMC free article] [PubMed] [Google Scholar]

29. Kessing LV, Hansen HV, Hvenegaard A, Christensen EM, Dam H, Gluud C, et al. Treatment in a specialised out-patient mood disorder clinic v standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202:212–219. [PubMed] [Google Scholar]

30. Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiat. 2000;33:8–13. [PubMed] [Google Scholar]

31. Ahrens B, Muller-Oerlinghausen B, Grof P. Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatry. 1993;163(suppl 21):27–29. [PubMed] [Google Scholar]

32. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA. 1998;95:8363–8368. [PMC free article] [PubMed] [Google Scholar]

33. Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry. 2000;48:518–530. [PubMed] [Google Scholar]

34. Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry. 2013;202:243–245. [PubMed] [Google Scholar]

35. Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L, et al. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. Biol Psychiatry. 2013;73:144–152. [PMC free article] [PubMed] [Google Scholar]

36. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113:1237–1264. [PubMed] [Google Scholar]

37. El-Mallakh RS. Ion homeostasis and the mechanism of action of lithium. Clin Neurosci Res. 2004;4:227–231. [Google Scholar]

38. Schou M. Biology and pharmacology of the lithium ion. Pharmacol Rev. 1957;9:17–58. [PubMed] [Google Scholar]

39. Mendels J, Frazer A. Intracellular lithium concentration and clinical response: towards a membrane theory of depression. J Psychiatr Res. 1973;10:9–18. [PubMed] [Google Scholar]

40. Dorus E, Pandey GN, Frazer A, Mendels J. Genetic determinant of lithium ion distribution. I. An in vitro monozygotic-dizygotic twin study. Arch Gen Psychiatry. 1974;31:463–465. [PubMed] [Google Scholar]

41. Rihmer Z, Arato M, Szentistvanyi I, Banki CM. The red blood cell/plasma lithium ratio: marker of biological heterogeneity within bipolar affective illness? Psychiatr Res. 1982;6:197–201. [PubMed] [Google Scholar]

42. Spirtes MA. Lithium levels in monkey and human brain after chronic, therapeutic, oral dosage. Pharmacol Biochem Behav. 1976;5:143–147. [PubMed] [Google Scholar]

43. Ehrlich BE, Diamond JM. Lithium, membranes, and manic-depressive illness. J Membr Biol. 1980;52:187–200. [PubMed] [Google Scholar]

44. Ehrlich BE, Diamond JM. Lithium fluxes in human erythrocytes. Am J Physiol. 1979;237:C102–C110. [PubMed] [Google Scholar]

45. Fernandez-Moncada I, Barros LF. Non-preferential fuelling of the Na+/K+-ATPase pump. Biochem J. 2014;460:353–361. [PubMed] [Google Scholar]

46. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300–308. [PubMed] [Google Scholar]

47. Naydenov AV, MacDonald ML, Ongur D, Konradi C. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry. 2007;64(5):555–564. [PubMed] [Google Scholar]

48. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67:360–368. [PubMed] [Google Scholar]

49. Aperia A. New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. J Intern Med. 2007;261:44–52. [PubMed] [Google Scholar]

50. Zhang L, Zhang Z, Guo H, Wang Y. Na+/K+-ATPase-mediated signal transduction and Na+/K+-ATPase regulation. Fundam Clin Pharmacol. 2008;22:615–621. [PubMed] [Google Scholar]

51. Kirshenbaum GS, Clapcote SJ, Duffy S, Burgess CR, Petersen J, Jarowek KJ, et al. Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase alpha3 sodium pump. Proc Natl Acad Sci U S A. 2011;108:18144–18149. [PMC free article] [PubMed] [Google Scholar]

52. Antia IJ, Smith CE, Wood AJ, Aronson JK. The upregulation of Na+,K+-ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. J Affect Disord. 1995;34:33–39. [PubMed] [Google Scholar]

53. Looney SW, El-Mallakh RS. Meta-analysis of erythrocyte Na,K-ATPase activity in bipolar illness. Depress Anxiety. 1997;5:53–65. [PubMed] [Google Scholar]

54. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. Erythrocyte membrane sodium-potassium adenosine triphosphatase activity in affective disorders. J Neural Transm Gen Sect. 1992;89:209–218. [PubMed] [Google Scholar]

55. Linnoila M, MacDonald E, Reinila M, Leroy A, Rubinow DR, Goodwin FK. RBC membrane adenosine triphosphatase activities in patients with major affective disorders. Arch Gen Psychiatry. 1983;40:1021–1026. [PubMed] [Google Scholar]

56. Huang X, Lei Z, El-Mallakh RS. Lithium normalizes elevated intracellular sodium. Bipolar Disord. 2007;9:298–300. [PubMed] [Google Scholar]

57. Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:56–61. [PubMed] [Google Scholar]

58. Jope RS, Jenden DJ, Ehrlich BE, Diamond JM. Choline accumulates in erythrocytes during lithium therapy. N Engl J Med. 1978;299:833–834. [PubMed] [Google Scholar]

59. Jope R. Effects of lithium treatment in vitro and in vivo on acetylcholine metabolism in rat brain. J Neurochem. 1979;33:487–495. [PubMed] [Google Scholar]

60. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med. 1994;331:591–598. [PubMed] [Google Scholar]

61. Manji HK, Hsiao JK, Risby ED, Oliver J, Rudorfer MV, Potter WJ. The mechanisms of action of lithium: I: effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry. 1991;48:505–512. [PubMed] [Google Scholar]

62. Akiskal HS, Downs J, Jordan P, Watson S, Daugherty D, Pruitt DB. Affective disorders in referred children and younger siblings of manic-depressives. Arch Gen Psychiatry. 1985;42:996–1003. [PubMed] [Google Scholar]

63. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA. 1998;95:2642–2647. [PMC free article] [PubMed] [Google Scholar]

64. Young LT, Li PP, Kish SJ, Siu LP, Kamble A, Hornykiewcz O, et al. Cerebral cortex Gsa protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem. 1993;61:890–898. [PubMed] [Google Scholar]

65. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4:117–128. [PubMed] [Google Scholar]

66. Mork A, Geisler A. Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain. Eur J Pharmacol. 1989;168:347–354. [PubMed] [Google Scholar]

67. Mork A, Geisler A. Effects of GTP on Hormone-Stimulated Adenylate Cyclase Activity in Cerebral Cortex, Striatum, and Hippocampus from Rats Treated Chronically with Lithium. Biol Psychiatry. 1989;26:279–288. [PubMed] [Google Scholar]

68. Mork A, Geisler A. Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol. 1987;60:241–248. [PubMed] [Google Scholar]

69. Berridge MJ. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J. 1984;220:345–360. [PMC free article] [PubMed] [Google Scholar]

70. Berridge MJ. The biology and medicine of calcium signalling. Mol Cell Endocrinol. 1994;98:119–124. [PubMed] [Google Scholar]

71. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, et al. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem. 1996;66:2402–2409. [PubMed] [Google Scholar]

72. van Calker D, Belmaker RH. The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord. 2000;2:102–107. [PubMed] [Google Scholar]

73. Belmaker RH, Agam G, van CD, Richards MH, Kofman O. Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle: depletion by chronic lithium of brain inositol is specific to hypothalamus, and inositol levels may be abnormal in postmortem brain from bipolar patients. Neuropsychopharmacology. 1998;19:220–232. [PubMed] [Google Scholar]

74. Lubrich B, van-Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacol. 1999;21:519–529. [PubMed] [Google Scholar]

75. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl BJ, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry. 1999;156:1902–1908. [PubMed] [Google Scholar]

76. O’Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009;37:1133–1138. [PMC free article] [PubMed] [Google Scholar]

77. Schubert T, Stoll L, Muller WE. Therapeutic concentrations of lithium and carbamazepine inhibit cGMP accumulation in human lymphocytes. A clinical model for a possible common mechanism of action? Psychopharmacology (Berl) 1991;104:45–50. [PubMed] [Google Scholar]

78. Schubert T, Muller WE. Lithium but not cholinergic ligands influence guanylate cyclase activity in intact human lymphocytes. Biochem Pharmacol. 1990;39:439–444. [PubMed] [Google Scholar]

79. Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci. 2011;32:420–434. [PubMed] [Google Scholar]

80. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol. 2001;64:51–68. [PubMed] [Google Scholar]

81. Harvey BH, Carstens ME, Taljaard JJ. Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain. Neurochem Res. 1994;19:469–474. [PubMed] [Google Scholar]

82. Boer U, Cierny I, Krause D, Heinrich A, Lin H, Mayr G, et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacol. 2008;33:2407–2415. [PubMed] [Google Scholar]

83. Warsh JJ, Andreopoulos S, Li PP. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. Clin Neurosci Res. 2004;4:201–213. [Google Scholar]

84. Emamghoreishi M, Schlichter L, Li PP, Parikh S, Sen J, Kamble A, et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry. 1997;154(7):976–982. [PubMed] [Google Scholar]

85. Perova T, Kwan M, Li PP, Warsh JJ. Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers. Int J Neuropsychopharmacol. 2010;13:693–702. [PubMed] [Google Scholar]

86. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci. 2003;24:441–443. [PubMed] [Google Scholar]

87. Meffre D, Grenier J, Bernard S, Courtin F, Dudev T, Shackleford G, et al. Wnt and lithium: a common destiny in the therapy of nervous system pathologies? Cell Mol Life Sci. 2014;71:1123–1148. [PubMed] [Google Scholar]

88. Lang F, Strutz-Seebohm N, Seebohm G, Lang UE. Significance of SGK1 in the regulation of neuronal function. J Physiol. 2010;588:3349–3354. [PMC free article] [PubMed] [Google Scholar]

89. Anacker C, Cattaneo A, Musaelyan K, Zunszain PA, Horowitz M, Molteni R, et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2013;110:8708–8713. [PMC free article] [PubMed] [Google Scholar]

90. Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv. 2008;8:230–241. [PubMed] [Google Scholar]

91. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78:1219–1232. [PMC free article] [PubMed] [Google Scholar]

92. Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci. 2012;37:7–16. [PMC free article] [PubMed] [Google Scholar]

93. Mota de Freitas D, Castro MM, Geraldes CF. Is competition between Li and Mg2 the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? Acc Chem Res. 2006;39:283–291. [PubMed] [Google Scholar]

94. Layden B, Diven C, Minadeo N, Bryant FB, Mota-de-Freitas D. Li+/Mg2+ competition at therapeutic intracellular Li+ levels in human neuroblastoma SH-SY5Y cells. Bipolar Disord. 2000;2:200–204. [PubMed] [Google Scholar]

95. Dermitzakis ET. Cellular genomics for complex traits. Nat Rev Genet. 2012;13:215–220. [PubMed] [Google Scholar]

96. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000;356:1241–1242. [PubMed] [Google Scholar]

97. Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord. 2012;14:261–270. [PMC free article] [PubMed] [Google Scholar]

98. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biol Psychiatry. 2000;48:1–8. [PubMed] [Google Scholar]

99. Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O’Donovan C, et al. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatr Neurosci. 2012;37:185–192. [PMC free article] [PubMed] [Google Scholar]

100. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274:6039–6042. [PubMed] [Google Scholar]

101. Martinsson L, Wei Y, Xu D, Melas PA, Mathe AA, Schalling M, et al. Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry. 2013;3:e261. [PMC free article] [PubMed] [Google Scholar]

102. Maurer IC, Schippel P, Volz HP. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009;11:515–522. [PubMed] [Google Scholar]

103. Wood GE, Young LT, Reagan LP, Chen B, McEwen BS. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci U S A. 2004;101:3973–3978. [PMC free article] [PubMed] [Google Scholar]

104. Deshauer D, Grof E, Alda M, Grof P. Patterns of DST positivity in remitted affective disorders. Biol Psychiatry. 1999;45:1023–1029. [PubMed] [Google Scholar]

105. Bauer M, Alda M, Priller J, Young LT. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiat. 2003;36(Suppl 3):S250–S254. [PubMed] [Google Scholar]

106. Hajek T, Bauer M, Simhandl C, Rybakowski J, O’Donovan C, Pfennig A, et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med. 2014;44:507–517. [PubMed] [Google Scholar]

107. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000;48:593–604. [PubMed] [Google Scholar]

108. McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. J Biol Rhythms. 2012;27:339–352. [PubMed] [Google Scholar]

109. Seggie J, Werstiuk E, Grota L, Brown GM. Chronic lithium treatment and twenty-four hour rhythm of serum prolactin, growth hormone and melatonin in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7:827–830. [PubMed] [Google Scholar]

110. Kasahara T, Kubota M, Miyauchi T, Noda Y, Mouri A, Nabeshima T, et al. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry. 2006;11:577–593. [PubMed] [Google Scholar]

111. Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry. 1999;4:21–25. [PubMed] [Google Scholar]

112. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet. 2002;359:241–247. [PubMed] [Google Scholar]

113. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942–947. [PubMed] [Google Scholar]

114. Garnham J, Munro A, Slaney C, MacDougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. J Affect Disord. 2007;104:185–190. [PubMed] [Google Scholar]

115. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry Suppl. 2001;41:s184–s190. [PubMed] [Google Scholar]

116. Licht RW, Vestergaard P, Brodersen A. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord. 2008;10:79–86. [PubMed] [Google Scholar]

117. Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord. 1999;54:87–96. [PubMed] [Google Scholar]

118. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5 year prospective study of 402 patients at a lithium clinic. Am J Psychiatry. 1998;155:30–35. [PubMed] [Google Scholar]

119. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry. 1993;163(Suppl 21):16–19. [PubMed] [Google Scholar]

120. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol. 1996;16:24S–31S. [PubMed] [Google Scholar]

121. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium. 1992;3:15–21. [Google Scholar]

122. McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010;11:1439–1465. [PubMed] [Google Scholar]

123. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7:404–417. [PubMed] [Google Scholar]

124. Passmore M, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003;5:110–114. [PubMed] [Google Scholar]

125. Alda M, Grof P, Grof E. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium. Biol Psychiatry. 1998;44:361–363. [PubMed] [Google Scholar]

126. Rohayem J, Bayle JF, Richa S. Predictors of prophylactic response to lithium. Encephale. 2008;34:394–399. [PubMed] [Google Scholar]

127. Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med. 2005;35:1685–1694. [PubMed] [Google Scholar]

128. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126:983–987. [PubMed] [Google Scholar]

129. Berghofer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008;69:1860–1868. [PubMed] [Google Scholar]

130. Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord. 1994;32:85–95. [PubMed] [Google Scholar]

131. Alda M, Grof P, Rouleau GA, Turecki G, Young LT. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1038–1045. [PubMed] [Google Scholar]

132. McKnew DH, Cytryn L, Buchsbaum MS, Hamovit J, Lamour M, Rapoport JL, et al. Lithium in children of lithium-reponding parents. Psychiatr Res. 1981;4:171–180. [PubMed] [Google Scholar]

133. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Can J Psychiatry. 2007;52:369–376. [PubMed] [Google Scholar]

134. Kruger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry. 2006;163:257–264. [PubMed] [Google Scholar]

135. Severino G, Squassina A, Costa M, Pisanu C, Calza S, Alda M, et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013;14:655–674. [PubMed] [Google Scholar]

136. Geoffroy PA, Bellivier F, Leboyer M, Etain B. Can the response to mood stabilizers be predicted in bipolar disorder? Front Biosci (Elite Ed) 2014;6:120–138. [PubMed] [Google Scholar]

137. Manchia M, Squassina A, Congiu D, Chillotti C, Ardau R, Severino G, et al. Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neurosci Lett. 2009;467:67–71. [PubMed] [Google Scholar]

138. Campos-de-Sousa S, Guindalini C, Tondo L, Munro J, Osborne S, Floris G, et al. Nuclear receptor rev-erb-{alpha} circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder. J Biol Rhythms. 2010;25:132–137. [PubMed] [Google Scholar]

139. McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke DF, Welsh DK, Kelsoe JR. Functional genetic variation in the Rev-Erbalpha pathway and lithium response in the treatment of bipolar disorder. Genes Brain Behav. 2011;10:852–861. [PMC free article] [PubMed] [Google Scholar]

140. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett. 2005;376:51–55. [PubMed] [Google Scholar]

141. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. The Pharmacogenomics Journal. 2001;1:71–77. [PubMed] [Google Scholar]

142. Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep. 2005;57:124–127. [PubMed] [Google Scholar]

143. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett. 2006;403:288–293. [PubMed] [Google Scholar]

144. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiat. 2005;38:166–170. [PubMed] [Google Scholar]

145. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B (Neuropsychiatr Genet) 2008;147B:500–504. [PMC free article] [PubMed] [Google Scholar]

146. Li M, Luo XJ, Rietschel M, Lewis CM, Mattheisen M, Muller-Myhsok B, et al. Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Mol Psychiatry. 2014;19:452–461. [PMC free article] [PubMed] [Google Scholar]

147. Kakiuchi C, Kato T. Lithium response and -116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder. Int J Neuropsychopharmacol. 2005;8:631–632. [PubMed] [Google Scholar]

148. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol. 2006;9:83–88. [PubMed] [Google Scholar]

149. Ewald H, Wang AG, Vang M, Mors O, Nyegaard M, Kruse TA. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr Genet. 1999;9:23–34. [PubMed] [Google Scholar]

150. Morissette J, Villeneuve A, Bordeleau L, Rochette D, Laberge C, Gagne B, et al. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet B (Neuropsychiatr Genet) 1999;88:567–587. [PubMed] [Google Scholar]

151. Lopez de Lara C, Jaitovich-Groisman I, Cruceanu C, Mamdani F, Lebel V, Yerko V, et al. Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. Int J Neuropsychopharmacol. 2010;13:1397–1410. [PMC free article] [PubMed] [Google Scholar]

152. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014;370:119–128. [PubMed] [Google Scholar]

153. Ikeda M, Kondo K, Iwata N. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014;370:1856–1857. [PubMed] [Google Scholar]

154. Consortium on Lithium Genetics. Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014;370:1857–1859. [PMC free article] [PubMed] [Google Scholar]

155. Ferreira MA, O’Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40(9):1056–1058. [PMC free article] [PubMed] [Google Scholar]

156. Muhleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014;5:3339. [PubMed] [Google Scholar]

157. Nanavati D, Austin DR, Catapano LA, Luckenbaugh DA, Dosemeci A, Manji HK, et al. The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome. J Neurochem. 2011;119:617–629. [PMC free article] [PubMed] [Google Scholar]

158. McQuillin A, Rizig M, Gurling HMD. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007;17:605–617. [PubMed] [Google Scholar]

159. Leussis MP, Berry-Scott EM, Saito M, Jhuang H, de HG, Alkan O, et al. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry. 2013;73:683–690. [PubMed] [Google Scholar]

160. Toker L, Belmaker RH, Agam G. Gene-expression studies in understanding the mechanism of action of lithium. Expert Rev Neurother. 2012;12:93–97. [PubMed] [Google Scholar]

161. Farah R, Khamisy-Farah R, Amit T, Youdim MB, Arraf Z. Lithium’s gene expression profile, relevance to neuroprotection A cDNA microarray study. Cell Mol Neurobiol. 2013;33:411–420. [PubMed] [Google Scholar]

162. Li PP. Transcriptional mechanisms of lithium action: therapeutic implications. Clin Neurosci Res. 2004;4:271–280. [Google Scholar]

163. Einat H. New ways of modeling bipolar disorder. Harv Rev Psychiatry. 2014;22:348–352. [PubMed] [Google Scholar]

164. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009;166:718–725. [PMC free article] [PubMed] [Google Scholar]

165. Squassina A, Manchia M, Borg J, Congiu D, Costa M, Georgitsi M, et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011;12:1559–1569. [PubMed] [Google Scholar]

166. Schulze T. Genomic and phenomic correlates of lithium response in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. Bipolar Disord. 2014;16(S1):26. (abstract) [Google Scholar]

167. Bergen S, Song J, Lichtenstein P, Landen M. Genome-wide association study of lithium response in a Swedish population. Bipolar Disord. 2014;16(S1):64. (abstract) [Google Scholar]

Which of the following terms is used to describe therapy techniques that research has proven effective for the treatment of psychological disorders?

Which of the following are components of dialectical behavioral therapy DBT )? Correct answer s?

What are some of the drawbacks of using Ritalin to treat attention deficit hyperactivity disorder ADHD?

Which of the following factors may put a person at risk for developing borderline personality?